Brant Inman

Overview:

Clinical research interests:
Clinical trials of novel diagnostic tests and therapies for genitourinary malignancies, with a strong focus on bladder cancer.

Basic science research interests:
Immune therapies for cancer, hyperthermia and heat-based treatment of cancer, molecular biology of genitourinary cancers, novel diagnostics and therapies for genitourinary cancers

Positions:

Cary N. Robertson, MD, Associate Professor

Surgery, Urology
School of Medicine

Professor of Surgery

Surgery, Urology
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

B.S. 1999

University of Alberta (Canada)

M.D. 2000

University of Alberta (Canada)

M.S. 2011

Mayo Clinic, Alix School of Medicine

Residency, Urology

Universite Laval (Canada)

Fellowship, Urologic Oncology

Mayo Clinic

Grants:

Phase II Trial of Aerobic Training in Metastatic Breast Cancer

Administered By
Radiation Oncology
Awarded By
National Institutes of Health
Role
Investigator
Start Date
End Date

PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY BLADDER CANCER

Administered By
Surgery, Urology
Awarded By
Genentech, Inc.
Role
Principal Investigator
Start Date
End Date

Phase 2 Study of BC-819 in Patients with Non-Muscle Invasive Bladder Cancer Whose Disease is Unresponsive to Bacillus Calmette-Guerin

Administered By
Surgery, Urology
Role
Principal Investigator
Start Date
End Date

A PHASE Ib/II, OPEN-LABEL STUDY OF THE SAFETY AND PHARMACOLOGY OF ATEZOLIZUMAB ADMINISTERED WITH OR WITHOUT BACILLE CALMETTE-GUÉRIN IN PATIENTS WITH HIGH-RISK NON¿MUSCLEINVASIVE BLADDER CANCER

Administered By
Surgery, Urology
Awarded By
Genentech, Inc.
Role
Principal Investigator
Start Date
End Date

TAR-200 Study

Administered By
Surgery, Urology
Awarded By
TARIS Biomedical, LLC
Role
Principal Investigator
Start Date
End Date

Publications:

Perioperative neurocognitive and functional neuroimaging trajectories in older APOE4 carriers compared with non-carriers: secondary analysis of a prospective cohort study.

BACKGROUND: Cognitive dysfunction after surgery is a major issue in older adults. Here, we determined the effect of APOE4 on perioperative neurocognitive function in older patients. METHODS: We enrolled 140 English-speaking patients ≥60 yr old scheduled for noncardiac surgery under general anaesthesia in an observational cohort study, of whom 52 underwent neuroimaging. We measured cognition; Aβ, tau, p-tau levels in CSF; and resting-state intrinsic functional connectivity in six Alzheimer's disease-risk regions before and 6 weeks after surgery. RESULTS: There were no significant APOE4-related differences in cognition or CSF biomarkers, except APOE4 carriers had lower CSF Aβ levels than non-carriers (preoperative median CSF Aβ [median absolute deviation], APOE4 305 pg ml-1 [65] vs 378 pg ml-1 [38], respectively; P=0.001). Controlling for age, APOE4 carriers had significantly greater preoperative functional connectivity than non-carriers between several brain regions implicated in Alzheimer's disease, including between the left posterior cingulate cortex and left angular gyrus (β [95% confidence interval, CI], 0.218 [0.137-0.230]; PFWE=0.016). APOE4 carriers, but not non-carriers, experienced significant connectivity decreases from before to 6 weeks after surgery between several brain regions including between the left posterior cingulate cortex and left angular gyrus (β [95% CI], -0.196 [-0.256 to -0.136]; PFWE=0.001). Most preoperative and postoperative functional connectivity differences did not change after controlling for preoperative CSF Aβ levels. CONCLUSIONS: Postoperative change trajectories for cognition and CSF Aβ, tau or p-tau levels did not differ between community dwelling older APOE4 carriers and non-carriers. APOE4 carriers showed greater preoperative functional connectivity and greater postoperative decreases in functional connectivity in key Alzheimer's disease-risk regions, which occur via Aβ-independent mechanisms.
Authors
Browndyke, JN; Wright, MC; Yang, R; Syed, A; Park, J; Hall, A; Martucci, K; Devinney, MJ; Moretti, EW; Whitson, HE; Cohen, HJ; Mathew, JP; Berger, M; MADCO-PC Investigators,
MLA Citation
URI
https://scholars.duke.edu/individual/pub1496919
PMID
34535274
Source
pubmed
Published In
Bja: British Journal of Anaesthesia
Published Date
DOI
10.1016/j.bja.2021.08.012

Plasmonic gold nanostars for synergistic photoimmunotherapy to treat cancer

Cancer is the second leading cause of death and there is an urgent need to improve cancer management. We have developed an innovative cancer therapy named Synergistic Immuno Photothermal Nanotherapy (SYMPHONY) by combining gold nanostars (GNS)-mediated photothermal ablation with checkpoint inhibitor immunotherapy. Our previous studies have demonstrated that SYMPHONY photoimmunotherapy not only treats the primary tumor but also dramatically amplifies anticancer immune responses in synergy with checkpoint blockade immunotherapy to treat remote and unresectable cancer metastasis. The SYMPHONY treatment also induces a 'cancer vaccine' effect leading to immunologic memory and prevents cancer recurrence in murine animal models. This manuscript provides an overview of our research activities on the SYMPHONY therapy with plasmonic GNS for cancer treatment.
Authors
Liu, Y; Chorniak, E; Odion, R; Etienne, W; Nair, SK; Maccarini, P; Palmer, GM; Inman, BA; Vo-Dinh, T
MLA Citation
Liu, Y., et al. “Plasmonic gold nanostars for synergistic photoimmunotherapy to treat cancer.” Nanophotonics, vol. 10, no. 12, Sept. 2021, pp. 3295–302. Scopus, doi:10.1515/nanoph-2021-0237.
URI
https://scholars.duke.edu/individual/pub1496639
Source
scopus
Published In
Nanophotonics
Volume
10
Published Date
Start Page
3295
End Page
3302
DOI
10.1515/nanoph-2021-0237

LUMINOS-103: A basket trial evaluating the safety and efficacy of PVSRIPO in patients with advanced solid tumors.

Authors
Inman, BA; Balar, AV; Milowsky, MI; Pruthi, RS; Polasek, MJ; Morris, SR; Mixson, L; Orr, K; Woodson, EM; Kelly, AT; Nichols, G
MLA Citation
URI
https://scholars.duke.edu/individual/pub1496554
Source
wos-lite
Published In
Cancer Research
Volume
81
Published Date

Subgroup analyses of the phase 3 study of intravesical nadofaragene firadenovec in patients with high-grade, BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)

Authors
Narayan, V; Boorjian, S; Alemozaffer, M; Konety, BR; Gomella, L; Kamat, AM; Lerner, SP; Svatek, RS; Karsh, L; Canter, D; Lotan, Y; Inman, BA; Yang, M; Garcia-Horton, V; Sawutz, D; Parker, N; Dinney, CPN
URI
https://scholars.duke.edu/individual/pub1494594
Source
wos-lite
Published In
European Urology
Volume
79
Published Date
Start Page
S1026
End Page
S1027

Significant anti-adenovirus antibody response positively correlates with efficacy in patients treated with nadofaragene firadenovec for high-grade BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)

Authors
Narayan, V; Boorjian, S; Alemozaffer, M; Konety, BR; Gomella, L; Kamat, AM; Lerner, SP; Svatek, RS; Karsh, L; Canter, D; Lotan, Y; Inman, BA; Yang, M; Garcia-Horton, V; Sawutz, D; Parker, N; Dinney, CPN
URI
https://scholars.duke.edu/individual/pub1494595
Source
wos-lite
Published In
European Urology
Volume
79
Published Date
Start Page
S1028
End Page
S1029

Research Areas:

BCG Vaccine
Cancer Vaccines
Carcinoma, Renal Cell
Clinical Trial
Cystectomy
Immunotherapy
Immunotherapy, Adoptive
Kidney Neoplasms
Magnetic nanoparticle hyperthermia
Metastasectomy
Nephrectomy
Penile Neoplasms
Prostate
Prostatic Neoplasms
Testicular Diseases
Testicular Neoplasms
Thermotherapy
Urethral Neoplasms
Urinary Bladder Neoplasms
Urinary Diversion
Urologic Neoplasms
Urology